Aberrant Gene Expression Prostate Carcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

5000 participants

Study Classification

OBSERVATIONAL

Study Start Date

1995-04-30

Study Completion Date

2030-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of the study is to gain a better understanding of the molecular changes responsible for causing prostate cancer and that examination of tissue and blood samples will help in the development of improved screening and therapeutic approaches.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Molecular Profiling in Prostate Cancer

NCT04983628

Prostate Cancer Metastatic Prostate Cancer Recurrent Germline BRCA1 Gene Mutation +2 more

UNKNOWN

Prostate Cancer Genomic Heterogeneity

NCT02022371

PROSTATE CANCER

COMPLETED PHASE1/PHASE2

Analysis of Prostate Cancer Short-Term Cultures Using Molecular Cytogenetic Methods

NCT00022919

Prostate Cancer

COMPLETED

DNA Changes in Patients With Prostate Cancer

NCT00899184

Prostate Cancer

COMPLETED

Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer

NCT00003329

Breast Cancer Colorectal Cancer Lung Cancer +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The goal of this study is to identify novel genetic elements that are aberantly expressed throughout prostatic neoplastic progression. The approaches proposed exploit the known familial arm of prostatic cancer, using established molecular genetic approaches, and extend these studies to sporadic prostatic cancer using a novel technique of differential display. Application of the latter technique to colon cancer in the American population establishes this tumor type as a high priority for scientific investigation and this study is part of an initiative to address this problem. Presently the studies in the field of prostate are under-represented. The collection of tissue samples from patients diagnosed with prostate cancer. Patients will also provide a blood sample at the time of their surgery and potentially post-op from 6 mos to 5 years. Samples will also be obtained from patients who's biopsy turns out to be non-prostate cancer. These samples will be obtained shortly following the biopsy out to 6 months after the biopsy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed prostate cancer undergoing prostatectomy
* Suspicion of prostate cancer undergoing biopsy - negative biopsy
* Health volunteer (control group) - blood sample for PSA

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes